Mycotopia Therapies, Inc.

As of September 30, 2024, Mycotopia Therapies, Inc. has 14.90M shares outstanding.

These figures are as of September 30, 2024.

These figures are as of September 30, 2024. Mycotopia Therapies, Inc. trades at an EV/FCF ratio of 33.42, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of September 30, 2024, Mycotopia Therapies, Inc. maintains a current ratio of 0.04, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -37.66, indicating conservative leverage, while an interest coverage ratio of -2.38 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -168.09, reflecting losses generated across the asset base.

These figures cover the twelve months ended September 30, 2024. Free cash flow yield is negative at -85.19: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -50.27, meaning Mycotopia Therapies, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Mycotopia Therapies, Inc.'s most recent stock split took place on May 1, 2014 with a 1:2 split ratio.

As of September 30, 2024, Mycotopia Therapies, Inc. has an Altman Z-Score of -121.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.